April 23, 2018 Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection
February 22, 2018 Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results
February 15, 2018 Synthetic Biologics to Report 2017 Year End Operational Highlights and Financial Results on February 22, 2018
November 1, 2017 Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results
October 25, 2017 Synthetic Biologics to Report Third Quarter 2017 Operational Highlights and Financial Results on November 1, 2017
September 12, 2017 Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing
August 29, 2017 Synthetic Biologics Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017
